CLINICAL_TRIALS
trial_result
· 2023-09-07
Clinical Trial Update: Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer [Phase 2]
Summary
Phase 2 trial evaluating durvalumab with or without tremelimumab in metastatic castration-resistant prostate cancer; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Canadian Cancer Trials Group | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-09-07